Annual report [Section 13 and 15(d), not S-K Item 405]

INCOME TAXES - Schedule of Components of Deferred Tax Assets (Details)

v3.25.4
INCOME TAXES - Schedule of Components of Deferred Tax Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Deferred tax assets    
Net operating loss carryforwards $ 216,008 $ 222,744
Orphan drug and research and development credits 63,458 62,314
Capitalized research and development expenses 5,165 19,604
Deferred revenue 334 10,181
Deferred compensation 4,616 11,701
Other, net 3,296 2,751
Deferred tax liabilities    
Others (327) (61)
Total net deferred tax assets 292,550 329,234
Less: valuation allowance (46,698) (329,234)
Deferred tax assets, net of allowance $ 245,852 $ 0